AbbVie Inc. reported new positive data from a phase 2b study on upadacitinib in atopic dermatitis, a chronic inflammatory skin disease.
The North Chicago, Ill.-based company said three different doses of the drug worked better than placebo after 16 weeks. The dose-ranging trial enrolled patients with moderate to severe atopic dermatitis, or eczema, which is characterized by red, itchy crusty and dry skin.
Participants received either placebo or upadacitinib in 7.5 milligram, 15 mg and 30 mg doses. The company reported a 23% improvement in eczema symptoms in the placebo group at week 16, compared to 39%, 62% and 74% improvement at escalating doses, respectively.
AbbVie said the most common side effects for upadacitinib were upper respiratory tract infection, atopic dermatitis worsening and acne.
The company presented the new data at the 2018 American Academy of Dermatology annual meeting in San Diego.